Møtemeny

JAKADEMi

Cytokiner JAK-signalering JAK-hemmere JAK-selektivitet JAK-hemmere - bivirkninger og sikkerhet Litteratur Cytokine Signalling Forum (CSF)  Spør JAK Møtemeny JAKADEMi

JAKADEMi webinar

• JAKADEMi Bullitin

  • JAKADEMi Bulletin: 1133 - kort oppsummert
  • JAKADEMi Bulletin: Abrocitinib og vaksinasjon
  • JAKADEMi Bulletin: Forventet effekt med tofacitinib
  • JAKADEMi Bulletin: Hva er Cibinqo
  • JAKADEMi Bulletin: Tofa-UC-Dosering
• BSR Finckh Importance of RWE in RA
• BSR Finckh RCT vs RWE
• ECCO Lees AI and machine learning within UC
• ECCO Lees_Regulatory updates for tofa
• ECCO Taxonera JAKi - RCT and RWD
• Galloway 1133 in RA-perspective
• JAK Leadership Webinar Choy JAK Selectivity
• Lees 1133 in UC-perspective
• Treat to Target - Part 1-6
• Treat to Target - Part 1
• Treat to Target - Part 2
• Treat to Target - Part 3a
• Treat to Target - Part 3b
• Treat to Target - Part 4
• Treat to Target - Part 5
• Treat to Target - Part 6
• Tofacitinib citrate and infection
• The value of real-world data
• Sleeve hjelpemiddel for Enbrel MyClic
• Physician-Patient relationship in the digital world
• JAKi-treatment within RA
• Introduction to infections in RA patients